Northland Securities analyst Carl Byrnes maintained a Buy rating on Aridis Pharmaceuticals Inc (ARDS) today and set a price target of $40. The company’s shares closed yesterday at $10.56.
Byrnes commented:
“We anticipate interim data from AR-301 P3 study in 1Q20, w/ TLR by year-end 2020.”
According to TipRanks.com, Byrnes is a 1-star analyst with an average return of -4.9% and a 20.7% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Flexion Therapeutics, and Heron Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aridis Pharmaceuticals Inc with a $25 average price target, which is a 136.7% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $25 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.85 and a one-year low of $7.59. Currently, Aridis Pharmaceuticals Inc has an average volume of 4,568.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.
